Dr. James C. Larocque, M.D.
Endocrinology & Diabetes (Endocrinology, Diabetes & Metabolism Physician)
- Medicare participating
At a glance
- Years since graduation
- 52
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 895
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Endocrinology, Diabetes & Metabolism Physician primary
VA license 0101034393
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Sentara Norfolk General Hospital Norfolk, VA
- Sentara Obici Hospital Suffolk, VA
- Bon Secours Maryview Medical Center Portsmouth, VA
- Bon Secours Harbour View Medical Center Suffolk, VA
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 895
- Services billed
- 5,215
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 1,400 | 687 |
| Blood glucose (sugar) test performed by hand-held instrument | 1,039 | 453 |
| Hemoglobin a1c level | 847 | 401 |
| Blood test, lipids (cholesterol and triglycerides) | 836 | 394 |
| Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | 352 | 163 |
| Established patient office or other outpatient visit, 20-29 minutes | 215 | 176 |
| Ultrasound scan of head and neck soft tissue | 139 | 119 |
| Established patient office or other outpatient visit, 30-39 minutes | 94 | 70 |
| Influenza vaccine, quadrivalent derived from cell cultures, preservative and antibiotic free | 70 | 70 |
| Administration of influenza virus vaccine | 69 | 69 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Levothyroxine Sodium Other prescribers in Chesapeake, VA | 855 |
| Lantus Solostar (insulin glargine,hum.rec.anlog) Other prescribers in Chesapeake, VA | 525 |
| Jardiance (empagliflozin) Other prescribers in Chesapeake, VA | 366 |
| Metformin Hcl Other prescribers in Chesapeake, VA | 360 |
| Ozempic (semaglutide) Other prescribers in Chesapeake, VA | 293 |
| Trulicity (dulaglutide) Other prescribers in Chesapeake, VA | 289 |
| Pioglitazone Hcl Other prescribers in Chesapeake, VA | 274 |
| Liothyronine Sodium Other prescribers in Chesapeake, VA | 236 |
| Synthroid (levothyroxine sodium) Other prescribers in Chesapeake, VA | 234 |
| Nano 2nd Gen Pen Needle (pen needle, diabetic) Other prescribers in Chesapeake, VA | 214 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 20 companies reported 85 payments worth $1,757 in total to this clinician.
| Corcept Therapeutics | $408 |
|---|---|
| Kyowa Kirin, Inc. | $215 |
| Mannkind Corporation | $178 |
| Amgen Inc. | $162 |
| Xeris Pharmaceuticals, Inc. | $110 |
| Chiesi USA, Inc. | $94.56 |
| AbbVie Inc. | $82.67 |
| Novo Nordisk Inc | $82.56 |
| Food and Beverage | $1,733 |
|---|---|
| Education | $24.04 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Neurocrine Biosciences, Inc. Feb 24, 2025 | Education CRENESSITY · Neuropsychiatry · in-kind | $24.04 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 3 companies. The companies reported $22,702 in research payments for these studies, mostly to the institutions running them.
- A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants
AbbVie Inc. · Active, not recruiting · NCT06345339 - M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants
AbbVie Inc. - CIP341 IMPACT2
Medtronic, Inc. - Study name not reported
Novo Nordisk As
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.